Cargando…
ODP175 COVID-19 Induced Euglycemic Diabetic Ketoacidosis in a Patient taking Sodium-Glucose Cotransporter-2 Inhibitors
From the U.S., under to American Diabetes Association, diabetic ketoacidosis (DKA) is accountable for around 6.3 percent of all hospitalization and 0.4% of all mortality annually. Unregulated hyperglycemia (>250 mg/dL), significant anion gaps, metabolic acidosis, and an increased plasma ketone co...
Autores principales: | Alqaisi, Sura, Rahman, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624885/ http://dx.doi.org/10.1210/jendso/bvac150.628 |
Ejemplares similares
-
ODP649 COVID-19 Induced Diabetic Ketoacidosis Which Unmasked Latent Autoimmune Diabetes In Adult
por: Alqaisi, Sura, et al.
Publicado: (2022) -
SAT110 Euglycemic Diabetes Ketoacidosis Associated With Sodium-glucose Cotransporter Inhibitors: A Case Series To Raise Awareness
por: Katwal, Dilasha, et al.
Publicado: (2023) -
ODP192 Empagliflozin associated Euglycemic Diabetic Ketoacidosis and the Terrible Triad
por: Nievera, Karl Homer, et al.
Publicado: (2022) -
ODP195 EUGLYCEMIC DIABETIC KETOACIDOSIS AFTER BARIATRIC SURGERY IN ASSOCIATION WITH USE OF SGLT2I.
por: Vaghasia, Nishit, et al.
Publicado: (2022) -
ODP244 SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges
por: Penna, Laurianne El Musa, et al.
Publicado: (2022)